Ponlimsi (denosumab-adet)

Introduction

Ponlimsi (denosumab-adet) is a RANK ligand (RANKL) inhibitor biosimilar to Prolia, approved by the FDA in March 2026. As a “biosimilar,” Ponlimsi is highly similar to the original biologic medication with no clinically meaningful differences in safety or effectiveness. It works by blocking a protein that causes bone breakdown, thereby increasing bone mass and strength. In the US, its arrival is expected to significantly lower the high costs of osteoporosis care, making bone-density protection more accessible to the aging population.

Usage and Indications

In the US, Ponlimsi is FDA-approved for:

• Postmenopausal Osteoporosis: Treatment of women at high risk for bone fracture.
• Male Osteoporosis: To increase bone mass in men with osteoporosis at high risk for fracture.
• Glucocorticoid-Induced Osteoporosis: For men and women at high risk for fracture who are taking long-term steroid medications (like prednisone).
• Bone Loss in Cancer Treatment: To increase bone mass in men receiving androgen deprivation therapy for prostate cancer and women receiving aromatase inhibitor therapy for breast cancer.

How to Take It (Dosage)

• Form: Subcutaneous injection (pre-filled syringe).
• Frequency: Once every 6 months.
• Administration: Ponlimsi must be administered by a healthcare professional (nurse or doctor). It is not designed for self-injection at home.
• Supplementation: US clinical guidelines strongly recommend that all patients on Ponlimsi take 1,000 mg of calcium and at least 400 IU of Vitamin D daily to prevent low blood calcium levels.

Side Effects

• Common: Back pain, pain in the arms or legs, and high cholesterol.
• Moderate: Bladder infections (UTIs) or skin reactions like dermatitis or rash.
• Serious (Rare):
  • Hypocalcemia: Critically low blood calcium levels.
  • ONJ (Osteonecrosis of the Jaw): Delayed healing of the jawbone, usually after dental surgery.
  • Atypical Femur Fractures: Unusual breaks in the thigh bone.

Precautions and Warnings

• Hypocalcemia: You must have your blood calcium levels checked before starting Ponlimsi. If your calcium is low, it must be corrected before the first dose.
• Severe Kidney Disease: Patients on dialysis or with severe kidney impairment are at a much higher risk for dangerous drops in calcium levels.
• Dental Work: It is highly recommended to have a dental exam and any necessary extractions completed before starting Ponlimsi to avoid jaw complications.
• The ‘Rebound’ Effect: Unlike some other bone drugs, you cannot simply “stop” Ponlimsi. Missing a dose or stopping treatment can lead to a rapid loss of bone density and a high risk of spinal fractures.

Interactions

• Immunosuppressants: Taking Ponlimsi with drugs that weaken the immune system may increase the risk of serious infections.
• Other Denosumab Products: Ponlimsi should not be used at the same time as Xgeva (a higher-dose denosumab used for bone cancer).

Storage

• Refrigeration: Store in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.
• Room Temperature: Once removed from the fridge, it must be used within 14 days. Do not freeze.

FAQ

1. Is Ponlimsi as good as Prolia? Yes. FDA approval as a “biosimilar” means it has been proven to provide the same bone-strengthening results as Prolia.
2. Why is it called a ‘Biosimilar’ and not a ‘Generic’? Biologics are made from living cells, making them too complex to be “generic.” Biosimilars are the equivalent “generic-style” version for these complex drugs.
3. Will my insurance switch me to Ponlimsi? Many US insurers and Medicare Advantage plans are expected to prefer Ponlimsi in 2026 because it is more cost-effective.
4. Do I still need my Prolia ‘Reminders’? Yes. Because it is given every 6 months, you should treat your Ponlimsi appointment with the same strict schedule as your Prolia shots.
5. Can I take it while pregnant? No. Ponlimsi can cause fetal harm. It is primarily used in postmenopausal women, but younger women on steroids must use effective birth control.
6. Does it cause ‘Jaw Death’? Osteonecrosis of the jaw is a very rare (approx. 1 in 1,000) side effect, usually triggered by invasive dental work while on the drug.
7. What if I’m late for my 6-month shot? Call your doctor immediately. Delaying the shot by even a few weeks can start to reverse the bone-building benefits.
8. Will it help my height? By preventing spinal “compression fractures,” it helps you maintain your current height as you age.
9. Can I exercise on Ponlimsi? Yes! Weight-bearing exercise (like walking or lifting light weights) works with the medication to strengthen your bones.
10. Is there a co-pay card? Yes, Teva (the manufacturer) launched a “Ponlimsi Savings Program” in April 2026 to help with out-of-pocket costs.